八大类药物不可与糖皮质激素合用!

2015-06-09 MedSci MedSci原创

安全用药知识你具备了吗?有些药明明是治疗疾病的,但如果不慎搭配,会变成毒药,甚至会有致命的可能。像糖皮质激素类药物很多,广泛应用于治疗皮炎、过敏性疾病、活动性风湿病、类风湿性关节炎等。功效多多,但实际上有八种药物不能与之搭配。有些会使药效降低,有些则会加重病情。下面和大家一起学习辨别这8类药物,做到安全用药。糖皮质激素类药物主要有氢化可的松、泼尼松、泼尼松龙、地塞米松、甲泼尼龙、曲安奈德、倍他米松

安全用药知识你具备了吗?有些药明明是治疗疾病的,但如果不慎搭配,会变成毒药,甚至会有致命的可能。像糖皮质激素类药物很多,广泛应用于治疗皮炎、过敏性疾病、活动性风湿病、类风湿性关节炎等。功效多多,但实际上有八种药物不能与之搭配。有些会使药效降低,有些则会加重病情。下面和大家一起学习辨别这8类药物,做到安全用药。

糖皮质激素类药物主要有氢化可的松、泼尼松、泼尼松龙、地塞米松、甲泼尼龙、曲安奈德、倍他米松等。此类药物具有抗炎、抗免疫、抗毒素、抗休克等作用,可用于肾上腺皮质功能减退,活动性风湿病、类风湿性关节炎、全身性红斑狼疮等胶原性疾病、严重的支气管哮喘、皮炎、过敏性疾病、急性白血病及感染性休克等,在临床中应用广泛。但在应用过程中,有些药物会与糖皮质激素类药物相互作用,在使用时应注意。

排钾利尿药  

这类药物主要有呋塞米、布美他尼、托拉塞米、氯噻酮、吲达帕胺、氢氯噻嗪、碳酸酐酶抑制剂等。糖皮质激素与这些排钾利尿药联用,可导致严重的低血钾,并且糖皮质激素的水钠潴留作用会减弱利尿药物的利尿效应。

抗真菌药
  
两性霉素B为抗人体深部组织真菌感染的药物,与糖皮质激素类药物合用,会导致或加重低血钾,使真菌病灶扩散,还会造成肝损害等。酮康唑、伊曲康唑可抑制糖皮质激素在体内的消除,抗真菌药物会抑制肝药酶对糖皮质激素在肝脏中的代谢,还有可能使内源性肾上腺皮质功能受到抑制,出现不良反应。

癫痫

如苯妥英钠、巴比妥等。这类药物为肝药酶诱导剂,可促使糖皮质激素类药物在肝脏中的排泄,使糖皮质激素类药物药效降低。

抗菌药
  
氨基糖甙类药物如与糖皮质激素合用,同样会导致糖皮质激素的作用降低,因氨基糖甙类等也为肝药酶诱导剂,也可使糖皮质激素类药物在肝脏中的代谢加快。氯霉素可使糖皮质激素效力增强,氯霉素为肝药酶抑制药,抑制糖皮质激素在肝脏中的代谢。此外,糖皮质激素可使甲硝唑从体内排泄加快,与肝药酶有关。

解热消炎镇痛药
  
阿司匹林、吲哚美辛、双氯芬酸、布洛芬、酮洛芬、萘普生等解热消炎镇痛药与糖皮质激素联用,易导致消化性溃疡等并发症。糖皮质激素可使水杨酸盐的消除加快,疗效也降低,与对氨基乙芬合用,可增加对肝脏的毒性。

降糖药

糖皮质激素可促进糖异生,减少外周组织对葡萄糖的摄取与利用,从而使血糖升高,减弱口服降血糖药物或胰岛素的作用。

强心甙
  
糖皮质激素与强心甙联用,能增加洋地黄毒性及心律失常的发生,其原因是糖皮质激素的水钠潴留和排钾作用而致。

蛋白质同化激素


如甲睾酮、比唑甲氢龙、达那唑、丙酸睾酮等,蛋白质同化激素与糖皮质激素合用,可增加水肿的发生率,诱发或加重痤疮。

其它


糖皮质激素能使灭活疫苗抗体减少,故在接种前2周内应禁止使用皮质激素类药物。还有些药物与糖皮质激素合用会发生药物间的相互作用,如单胺氧化酶抑制剂与糖皮质激素联用可能发生高血压危象;与抗凝剂联用,可降低抗凝作用等。所以使用糖皮质激素类药物时,要注意药物间的相互作用。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=38869, encodeId=23a938869f8, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29881651723, createdName=1ddcbc02m31(暂无匿称), createdTime=Wed Oct 14 21:28:00 CST 2015, time=2015-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701130, encodeId=a4c11e011309c, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sun Sep 13 06:22:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26992, encodeId=bb49269921a, content=好好上了一课,获益非浅!, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42d71587216, createdName=xwdon123, createdTime=Thu Jun 11 13:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600234, encodeId=54be1600234b3, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Jun 11 05:22:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26645, encodeId=026926645cf, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:04:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26523, encodeId=cbb426523bc, content=在临床上用激素特别多这次真的学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 09 15:37:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
    2015-10-14 1ddcbc02m31(暂无匿称)

    好!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=38869, encodeId=23a938869f8, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29881651723, createdName=1ddcbc02m31(暂无匿称), createdTime=Wed Oct 14 21:28:00 CST 2015, time=2015-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701130, encodeId=a4c11e011309c, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sun Sep 13 06:22:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26992, encodeId=bb49269921a, content=好好上了一课,获益非浅!, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42d71587216, createdName=xwdon123, createdTime=Thu Jun 11 13:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600234, encodeId=54be1600234b3, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Jun 11 05:22:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26645, encodeId=026926645cf, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:04:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26523, encodeId=cbb426523bc, content=在临床上用激素特别多这次真的学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 09 15:37:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=38869, encodeId=23a938869f8, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29881651723, createdName=1ddcbc02m31(暂无匿称), createdTime=Wed Oct 14 21:28:00 CST 2015, time=2015-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701130, encodeId=a4c11e011309c, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sun Sep 13 06:22:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26992, encodeId=bb49269921a, content=好好上了一课,获益非浅!, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42d71587216, createdName=xwdon123, createdTime=Thu Jun 11 13:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600234, encodeId=54be1600234b3, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Jun 11 05:22:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26645, encodeId=026926645cf, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:04:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26523, encodeId=cbb426523bc, content=在临床上用激素特别多这次真的学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 09 15:37:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
    2015-06-11 xwdon123

    好好上了一课,获益非浅!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=38869, encodeId=23a938869f8, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29881651723, createdName=1ddcbc02m31(暂无匿称), createdTime=Wed Oct 14 21:28:00 CST 2015, time=2015-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701130, encodeId=a4c11e011309c, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sun Sep 13 06:22:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26992, encodeId=bb49269921a, content=好好上了一课,获益非浅!, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42d71587216, createdName=xwdon123, createdTime=Thu Jun 11 13:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600234, encodeId=54be1600234b3, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Jun 11 05:22:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26645, encodeId=026926645cf, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:04:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26523, encodeId=cbb426523bc, content=在临床上用激素特别多这次真的学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 09 15:37:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=38869, encodeId=23a938869f8, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29881651723, createdName=1ddcbc02m31(暂无匿称), createdTime=Wed Oct 14 21:28:00 CST 2015, time=2015-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701130, encodeId=a4c11e011309c, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sun Sep 13 06:22:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26992, encodeId=bb49269921a, content=好好上了一课,获益非浅!, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42d71587216, createdName=xwdon123, createdTime=Thu Jun 11 13:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600234, encodeId=54be1600234b3, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Jun 11 05:22:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26645, encodeId=026926645cf, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:04:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26523, encodeId=cbb426523bc, content=在临床上用激素特别多这次真的学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 09 15:37:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
    2015-06-09 huaxipanxing

    看看

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=38869, encodeId=23a938869f8, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29881651723, createdName=1ddcbc02m31(暂无匿称), createdTime=Wed Oct 14 21:28:00 CST 2015, time=2015-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701130, encodeId=a4c11e011309c, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Sun Sep 13 06:22:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26992, encodeId=bb49269921a, content=好好上了一课,获益非浅!, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42d71587216, createdName=xwdon123, createdTime=Thu Jun 11 13:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600234, encodeId=54be1600234b3, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Jun 11 05:22:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26645, encodeId=026926645cf, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:04:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26523, encodeId=cbb426523bc, content=在临床上用激素特别多这次真的学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 09 15:37:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
    2015-06-09 summer474cn

    在临床上用激素特别多这次真的学习了

    0

相关资讯

NEJM:撤退吸入糖皮质激素对慢性阻塞性肺疾病(COPD)频繁发作没有显著影响

长效支气管扩张剂联合应用糖皮质激素吸入被推荐用于重度慢性阻塞性肺疾病(COPD)的频繁发作。然而,在吸入糖皮质激素基础上,增加两种长效支气管扩张剂的益处还未得到验证。 最新一项新英格兰期刊上发表了最新研究成果,称为WISDOM 试验,这是一项为期12个月双盲,平行对照试验,共招募2485位慢性COPD急性发作史患者,接收三联治疗,包括tiotropium(噻托溴铵)(18 μg,每天一次

JCEM:关注糖皮质激素治疗——青少年先天性肾上腺增生患者常表现出心血管的异常及运动耐力受损

研究背景: 患有经典型先天性肾上腺增生(CAH)的患者需要终身接受糖皮质激素治疗,而该治疗方案对青少年患者心血管和代谢方面的影响从未被量化研究。 研究目的: 研究青少年CAH患者左心室形态及功能以及运动耐量的情况。 研究设计: 在一个第三方推荐的中心开展交叉横断面控制研究。 患者情况: 本研究共纳入患有经典CAH的20名患者平均年龄13.6±2.5岁以及2

Lancet:免疫性血小板减少症使用利妥昔单抗可改善治疗应答

原发免疫性血小板减少症(Immune thrombocytopenia,ITP)是一种免疫介导的自身抗体致敏的血小板被单核巨噬细胞系统破坏和血小板成熟释放障碍所致的疾病。虽然目前还相对缺乏利妥昔单抗(rituximab,美罗华)应用于ITP十分确切的治疗证据,利妥昔单抗作为一个未被临床指南正式认可的适用于本病治疗的药物也频繁应用于部分ITP患者当中,研究者在先前曾接受糖皮质激素免疫抑制治疗的未切脾

Diabetologia:糖皮质激素诱导的胰岛素抵抗降低肠促胰素效应

最近,有研究评估了在健康个体使用糖皮质激素诱导胰岛素抵抗造成进展性T2DM模型,评估肠促胰素效应。试验中,挑选19名健康、糖耐量正常的T2DM一级亲属作为受试者。 在地塞米松治疗前,所有受试者都要进行第1天的OGTT试验,接着是为期3天葡萄糖钳夹试验,分别向受试者静注GLP-1、GIP或NaCl,最后静注精氨酸来明确胰岛beta细胞的最大分泌功能。地塞米松治疗5天后,重复这4天的试验。总

Ann Rheum Dis:Meta分析揭示不同抗风湿药物的心血管事件风险差异

研究者为了明确心血管事件(CVEs)和抗风湿药物的关系,进行了一项系统评价和Meta分析。该研究中使用抗风湿治疗的患者人群为类风湿关节炎(RA)、银屑病关节炎(PsA)/银屑病(Pso)患者。研究者系统性检索了MEDLINE,EMBASE,Cochrane databases里1960到2012年12月份发表的随机对照研究和相关的重要会议记录(2010-2012,文献需包含确定的CVEs信息和使用

JAMA:糖皮质激素或可用于重症社区获得性肺炎急性期治疗

在发达国家,社区获得性肺炎在导致死亡的感染性中占主导地位。尽管积极的使用抗感染治疗,因其导致的住院病人死亡率依旧居高不下,尤其是重症肺炎和治疗失败的情况下。而重症社区获得性肺炎的病人,其治疗失败通常与进行性炎症反应和更糟糕的临床结局有关。在这类治疗失败的病人中,可以使用糖皮质激素,去调节体内细胞因子的释放以抵抗炎症反应,达到治疗效果,但是目前对于糖皮质激素在这类人群中的运用仍存在争议。因此Anto